{
  "id": 3695,
  "text": "1698.Farley, J., et al.Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: 1698.Farley, J., et al.Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study.\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "顺铂（Cisplatin）与西妥昔单抗（Cetuximab）的联合使用正在晚期、复发或既往治疗的宫颈癌患者中被研究。这两种药物的组合旨在提高治疗效果，其中西妥昔单抗是一种针对表皮生长因子受体（EGFR）的单克隆抗体。EGFR在一些宫颈癌患者中的免疫组化表达水平与肿瘤的生物学行为及治疗反应密切相关。因此，通过评估EGFR的免疫组化表达，可以帮助筛选适合接受该联合方案治疗的患者，更好地个性化治疗策略并提高疗效。",
  "query": "在治疗晚期宫颈癌时，哪两种药物的联合使用正在被研究中，它们与表皮生长因子受体的免疫组化表达评估有何关联？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 在治疗晚期宫颈癌时，哪两种药物的联合使用正在被研究中，它们与表皮生长因子受体的免疫组化表达评估有何关联？\n\n<reference text>: 1698.Farley, J., et al.Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study.\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "顺铂（Cisplatin）与西妥昔单抗（Cetuximab）的联合使用正在晚期、复发或既往治疗的宫颈癌患者中被研究。这两种药物的组合旨在提高治疗效果，其中西妥昔单抗是一种针对表皮生长因子受体（EGFR）的单克隆抗体。EGFR在一些宫颈癌患者中的免疫组化表达水平与肿瘤的生物学行为及治疗反应密切相关。因此，通过评估EGFR的免疫组化表达，可以帮助筛选适合接受该联合方案治疗的患者，更好地个性化治疗策略并提高疗效。"
}